Please assess the completion status of the following clinical trial:

Trial Title: Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older.~2. Capable of giving informed consent and does provide informed consent.~3. Diagnosis of Meibomian Gland Disease~4. Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative urine pregnancy test is required within 7 days of the participant receiving first dose of study drug along with definite evidence of contraceptive use during the duration of the study. Women of reproductive age should use a method of birth control that is acceptable to the participant and the study doctor. This may include oral contraceptive pills, birth control implants, barrier methods or abstinence. If a participant suspects pregnancy after being enrolled, another pregnancy test will be administered. If the test is positive, the participant will be discontinued from the study immediately.~Exclusion Criteria:~1. Allergic to Brimonidine or any similar products, or excipients of Brimonidine~2. Currently receiving any Brimonidine preparation as a part of glaucoma management~3. Receiving or have received within 30 days any experimental systemic medication.~4. Active ocular infection or ocular allergies.~5. Any history of eyelid surgery or ocular surgery within the past 3 months.~6. Corneal epithelial defect larger than 1 mm2 in either eye.~7. Have active drug/alcohol dependence or abuse history.~8. Vulnerable populations, such as neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brimonidine 0.15% (Type: ACTIVE_COMPARATOR): Brimonidine 0.15% eye drops 2 times a day for 12 weeks
- Brimonidine 0.075% (Type: ACTIVE_COMPARATOR): Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).